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ABSTRACT
It is well known that radiotherapy provides successful pain relief in bone metastases. Advancements in imaging and 
radiotherapy delivery technology have enabled safe delivery of higher dose radiotherapy, which will produce more 
durable tumor control. Over the last decades stereotactic radiosurgery (SRS), which delivers high dose radiation, has 
been successfully used for the treatment of intracranial lesions. The good results obtained in SRS have led to 
development of extra cranial stereotactic radiosurgery known as stereotactic ablative body radiotherapy (SABR). This 
review paper enlightens indication, target definition, efficacy and toxicity in spinal SABR.
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ABSTRAK
Radioterapi telah terbukti sebagai modalitas yang dapat menghilangkan nyeri pada metastases tulang. Kemajuan 
dalam teknologi pencitraan dan pemberian radioterapi telah memungkinkan pemberian radioterapi dosis tinggi 
dengan aman, di mana hal ini dapat meningkatkan kontrol lokal. Selama dekade terakhir ini, stereotactic radiosurgery 
(SRS) yang memberikan radiasi dosis tinggi dinyatakan bermanfaat untuk tatalaksana berbagai kelainan intrakranial. 
Hasil cukup memuaskan yang diperoleh SRS mendorong untuk dikembangkan stereotactic radiosurgery ekstrakranial 
yang kemudian dikenal sebagai stereotactic ablative body radiotherapy (SABR). Tinjauan pustaka ini menjelaskan 
indikasi, target radiasi, efektivitas, dan efek samping pada prosedur SABR spinal.
Kata Kunci: spinal, metastases, stereotaktik, radioterapi
INTRODUCTION
Bone metastasis is one of manifestations, which is often found in malignancy patients. Bone metastasis can cause debilitating effects, especially if metastasis 
locates in the spine. This is because spinal metastasis can cause not only pain and 
pathologic fractures as a usual problem in bone metastasis but also spinal cord 
compression. Spinal cord compression can produce mild to severe neurological 
symptoms. Spinal metastases can be found in 30-50% of patients with malignancies.1-3
Radiotherapy has been recognized as an important modality in the treatment of 
bone metastasis. This is due to radiotherapy has been proved in pain relief in 50-
80% patients with bone metastasis. Moreover, one-third of patients can achieve 
complete pain relief.1-3
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This review paper enlightens the stereotactic 
ablative body radiotherapy (SABR) as an emerging 
modality in radiotherapy, and indication, target 
definition outcome and toxicity in spinal SABR.
MANAGEMENT DECISION IN BONE METASTASES
Spinal metastasis can cause spinal cord compression. 
In the past, treatment of spinal cord compression 
was with corticosteroids and radiotherapy. The role 
of surgical decompression was not yet known. Patchell 
et al conducted study to compare surgical decompression 
followed by radiotherapy with radiotherapy alone. 
The study shown that the decompression surgery 
can improve the ability to walk after treatment, and 
reduce the use of steroids and analgesics.2-4
The management of spinal metastasis requires 
multi-disciplinary approach involving surgery, radio-
therapy, chemotherapy and physical medicine and 
rehabilitation. The management decision in spinal 
metastasis needs to consider various aspects such 
as neurology, oncology, mechanical stability and 
systemic disease. These should be assessed before 
the commencement of treatment. Neurological 
functions can be assessed with degree of spinal cord 
compression, myelopathy and functional radiculopathy. 
The degree of spinal cord compression can be assessed 
by Magnetic Resonance Imaging (MRI) and it is 
classified based on Bilsky grading system. Oncology 
assessment address histopathology type of the tumor, 
which will determine the radiosensitivity of tumor in 
relation with conventional radiotherapy. Mechanical 
stability assesses for the possibility of pathologic 
fracture. Spinal instability can de defined as loss of 
spinal integrity as a result of a neoplastic process, 
which is associated with movement-related pain, 
symptomatic or progressive deformity and/or neural 
compromise under physiologic loads. Mechanical 
stability can be assessed with spine instability 
neoplastic score (SINS). Systemic disease assesses 
metastasis disease, comorbidities and performance 
status, which is related with patient survival.2,5
Table 1: Decision framework in spinal metastasis5
Neurologic Oncologic Mechanical Systemic Management decision
Low grade ESCC 
(epidural spinal cord 
compression) + no 
myelopathy 
Radiosensitive Stable cEBRT
Radiosensitive Unstable Stabilization followed by cEBRT
Radioresistant Stable SRS
Radioresistant Unstable Stabilization followed by SRS
High grade ESCC 
+/- myelopathy 
Radiosensitive Stable cEBRT
Radiosensitive Unstable Stabilization followed by cEBRT
Radioresistant Stable Able to tolerate surgery Decompression/stabilization followed by SRS
Radioresistant Stable Unable to tolerate surgery cEBRT
Radioresistant Unstable Able to tolerate surgery Decompression/stabilization followed by SRS
Radioresistant Unstable Unable to tolerate surgery Stabilization followed by cEBRT
ESCC: Epidural spinal cord compression; cEBRT: conventional external beam radiotherapy; SRS: stereotactic radiosurgery.
STEREOTACTIC ABLATIVE BODY RADIOTHERAPY 
(SABR)
The application of stereotactic radiosurgery was 
widely known when in 1967, when dr. Lars Leksell 
introduced GammaKnife in treating various intra-
cranial disorders. In concordance with the development 
of radiotherapy technology, a linear accelerator (LINAC) 
had been modified so it could also delivered cranial 
radiosurgery. The application of LINAC in cranial 
radiosurgery has been used since 1982. Because of 
satisfactory result in cranial radiosurgery, radiosurgery 
began to be used for extra-cranial abnormalities. It 
started since 1991 for cases of lung and liver tumors 
and it was known as stereotactic body radiotherapy 
(SBRT). Because we try to deliver high ablative dose, 
so it can also be referred as stereotactic ablative 
body radiotherapy (SABR).6,7
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SABR uses the stereotactic principle in radiotherapy 
delivery because the delivery of high ablative dose 
needs a high accuracy. Stereotactic is a concept 
that uses three-dimensional coordinate system to 
define the target location. Stereotactic 3-dimensional 
coordinates can be divided into external stereotactic 
coordinates that are usually attach to the fixation 
frame such as Allan Hamilton fixation method and 
internal stereotactic coordinate, which usually uses 
image-guidance localization method for the verification 
of the target. The image-guidance localization method 
can use either cone-beam CT-Scan or orthogonal with 
kilo voltage images (x-ray stereoscopic). Stereoscopic 
is a 3 dimensional measurement method using two 
or more 2-dimensional images intersect, which will 
produce a 3 dimensional coordinates for each image, 
which is intersecting.6-9
There are several characteristics in SABR such 
as high degree of accuracy because of stereotactic 
principle, high conformity to the shape of the target, 
fix immobilization, steep dose fall off outside the 
target and high ablative radiation dose. Because of 
high dose, it requires distance between the tumor 
and healthy organs so it allows for steep dose fall 
off and it can only be delivered in small-size tumor. 
SABR refers not only to single fraction but also 
hypofractionated up to 5 fractions.6-9
Figure 1: Spinal metastasis SABR delivered in a single fraction with 24 Gray(Gy) dose (red line).  
We can see steep dose fall off distribution between the vertebrae and the spinal cord (the purple line)9
There are several platforms that can perform 
SBRT such as LINAC system, Cyberknife, Novalis 
and TomoTherapy. All of these existing systems use 
the principle of image-guidance. The image guidance 
method applies the imaging technology to verify 
the position of the target before the radiotherapy 
delivery. LINAC and TomoTherapy is equipped with 
cone-beam CT-Scan for verification, while Novalis and 
Cyberknife uses orthogonal kV images for verification.7-9
INDICATION
SABR may be indicated in certain circumstances. 
SABR can be delivered if patient meet the following 
indication and there is no contraindications for 
SABR procedure. The following table illustrates 
some of the indications and contraindications for 
spinal metastases SABR based on evidence-based 
clinical guidelines from the American Society for 
Radiation Oncology (ASTRO).2,8
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In addition to the ASTRO criteria, we can also 
incorporate additional criteria based Radiation 
Therapy Oncology Group - 0631 (RTOG 0631), which 
stated that there should be a distance between the 
spinal cord and tumor ≥ 3 mm and paraspinal mass 
diameter should less than 5 cm.10
TARGET DEFINITION
MRI is recommended for target definition in 
spinal metastases SABR. In spinal SABR target 
definition, we must incorporate visible tumor mass 
with CT-Scan and MRI, including epidural and 
paraspinal mass and also adjacent area to account 
for subclinical tumor spread. International spine 
radiosurgery consortium has issued guidelines for 
target volume definition in spinal SABR. This 
guideline classifies vertebrae bones into six 
compartments, consists of body, the right pedicle, 
right transversus process and lamina, spinosus 
process, left transversus process and lamina and 
the left pedicle. In spinal SABR target definition, if 
the tumor mass close to adjacent compartment, we 
must include adjacent compartment in target volume 
to eliminate the possibility of microscopic spread. 
PTV margin should less than 3 mm because of fix 
immobilization and the application of image-guided. 
PTV margins can be adjusted in the area adjacent 
to the spinal cord so that there is a distance between 
tumor and spinal cord. It is useful for step dose 
fall off become possible.2,11
Figure 2: The anatomy classification system based on the compartment 
for target definition in spinal radiosurgery11
Target definition recommendation for postoperative 
spinal metastases SABR should involve all regions 
of preoperative lesions including bone, epidural 
extension and the adjacent compartment, which is 
possible to harbor microscopic disease. Internal 
fixation is not included in the target volume.12
Table 2: Summary of indications and contraindications for spinal metastasis SABR according to ASTRO guideline2
Characteristics Indication Contraindications
Radiology Spinal or paraspinal metastasis by MRI Spinal MRI cannot be done
No more than 2 consecutive or 3 noncontagious 
spine segments involved Epidural spinal cord or cauda equina compression
Spinal canal compromise > 25%
Unstable spinal requiring surgical stabilization
Tumor location within 5 mm of spinal cord or cauda 
equina (relative)
Patients Age ≥18 yo Active connective tissue disease (ex: scleroderma)
KPS ≥ 40 - 50 Worsening or progressive neurologic deficit
Medically inoperable or patient refused surgery Inability to lie flat on table for SABR
< 3 months life expectancy
Tumor Histo-pathologic confirmation of malignancy Radiosensitive tumor such as multiple myeloma
Biopsy of spine lesion if first suspected metastasis Extra spinal disease not eligible for further treatment 
Previous treatment Previous EBRT <45 Gy total dose Previous SBRT to same level
Failure of previous surgery at that level Systemic radionuclide delivery within 30 days before SBRT
Presence of gross residual disease after surgery EBRT within 90 days before SBRT
Chemotherapy within 30 days of SBRT
Abbreviation: KPS: Karnofsky performance scale, EBRT: external beam radiotherapy
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TREATMENT OUTCOME
SABR treatment effects for spinal metastases are 
not only in pain relief as conventional radiotherapy 
for bone metastases in general, but also for local 
control, spinal cord decompression and improvement 
of neurological function. Currently, there is no phase 
3 data compares SABR to conventional radiotherapy 
in spinal metastasis management. The available 
data are based on phase 2 data. Saghal et al. is 
still collecting data to compare SABR to conventional 
radiotherapy. This protocol compares SABR, which 
delivered 12 Gy/fraction for 2 fractions with 
conventional radiotherapy 4 Gy/fraction for 5 
fractions. The primary end-point is pain control.13
SABR showed a good response in pain relief. 
Wang et al. reported that patients with no pain 
were increased from 26% in pre-SABR group to 54% 
in post-SABR group, and also accompanied by a 
reduction in opioid use 8.9% at 6 months post-SABR. 
Ryu et al. reported that the overall pain control for 
1 year was 84% and median duration of pain relief 
at the treated level was 13.3 months.14,15
Yamada et al. reported SABR with 24 Gy dose 
in single fraction with a median follow-up of 15 
months; Local control rate was 90%; Median time 
to local failure was 9 months; and the median 
survival time was 15 months. In all cases of death 
were caused by systemic disease progression and 
not by the local failure. Wang et al. reported 1-year 
and 2-years progression free survival post-SABR was 
80.5% and 72.4% respectively.15,16
Ryu et al. evaluated not only pain response, but 
also tumor shrinkage response and improvement 
of neurological function. In this study, Ryu obtained 
tumor shrinkage response 2 months post-SABR was 
65 ± 14%. The tumor shrinkage caused thecal sac 
patency improved 20%. Also neurological function 
improved as much as 81%. When compared with 
the study by Patchell et al. overall ambulatory rate 
was 84% and it was almost comparable with study 
by Ryu et al., which overall intact rate was 81%.4,17
Table 3: Literature review of the spinal metastasis SABR outcome
Author & year N Dose/fraction Follow-up Pain response Local control Neurologic function
Tumor 
reduction
Yamada 
(MSKCC), 
2008.15
103 18 – 24 Gy/1 fraction
Median 15 
months NS 90% NS NS
Wang (MDACC), 
2012.14 149
27-30 Gy/3 
fractions
Median 15.9 
months
26% no pain 
pre SBRT 
increased to 
54% 6 months 
after SBRT 
(BPI)
Strong opioid 
use declined 
from 29.9% to 
20% 
I year PFS 
80.5%
2 year PFS 
72.4% 
NS NS
Ryu, 2008.16 49 10 – 16 Gy NS
Overall pain 
control 1 year: 
84%
NS NS NS
Ryu, 2010.17 62
12 – 20 Gy/1 
fraction 
Median 16 Gy
Median 11.5 
months NS NS
Improved in 
81%
65±14% at 
2 months
Ryu (RTOG 
0631), 2014.10 44
16 – 18 Gy/1 
fraction NS NS NS NS NS
NS: Not specify; BPI: brief pain inventory, MSKCC: Memorial Sloan Kattering Cancer Center;  
MDACC: MD Anderson Cancer Center; PFS: Progression free survival.
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TOXICITY
There are 2 toxicities which become an issue in 
spinal SABR, which are radiation myelopathy and 
vertebrae compression fracture. The other toxicity, 
which can occur in spinal SABR are related to the 
location of the lesion. Some example of other 
toxicities is cough, dyspepsia, esophagitis and 
pruritus, but they usually occur in low grade.10,18-20
Saghal et al. has issued guidance to predict 
radiation myelopathy after SABR according to thecal 
sac point maximum (Pmax). This model described 
radiation myelopathy probability of 1 – 5% for SABR 
single fraction up to five fractions. For single fraction 
SABR with Pmax of 9.2 Gy, the probability of 
myelopathy is nearly 9.2% and Pmax of 12.4 Gy, the 
probability of myelopathy is nearly 5%. For 
hypofractionated SABR in 3 fractions with the total 
Pmax of 14.8 Gy, the myelopathy probability is 1%, 
while the total Pmax of 20.3 Gy, the myelopathy 
probability is approximately 5%. American Association 
of Physicist in Medicine (AAPM) recommends D0.035 
cc as a maximum dose reference.18
Vertebral compression fractures occurs due to a 
decrease in vertebrae bone quality. This is associated 
with not only osteolytic and osteoblastic disease, 
but also radiotherapy. Radiotherapy can cause damage 
to the collagen, which leads in reduction in bone 
strength. SABR can also cause osteoradionecrosis 
of bone and tumor tissues. There are several factors 
predictors of this complications, which are vertebral 
body collapse ≥ 50%, SABR dose > 19 Gy, abnormal 
bone alignment and lytic bone lesion type.19,20
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CONCLUSION
SABR is an advanced technology in radiotherapy 
modalities in spinal metastasis management. It is 
delivered mainly in case, which meets the following 
criteria such as radio-resistant tumors, small size 
and low degree of spinal cord compression. The 
outcome of SABR is not only pain relief, but also 
local tumor control and improvement of neurological 
function as well as decompression of the spinal 
cord. The issue that we should keep in mind that 
SABR need latency period until the effect appears, 
which is represented by the improvement of clinical 
symptoms. If we need rapid response in high-grade 
spinal cord compression, surgery should be performed 
first. The advantage of SABR compared with 
conventional radiotherapy needs to be determined 
further.
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